SARS-CoV-2 testing in the Slovak Republic from March 2020 to September 2022 – summary of the pandemic trends

Nikola Janostiakova^{1*}, Andrej Gnip², Dominik Kodada¹, Rami Saade¹, Gabriela Blandova¹, Emilia Mikova², Elena Tibenska², Vanda Repiska¹ and Gabriel Minarik³

- ³ ¹Comenius University in Bratislava Faculty of Medicine, Department of Clinical Biology, Genetics
- 4 and Clinical Genetics, Bratislava, Slovakia
- ⁵ ²Medirex, a.s., Pezinok, Slovakia
- 6 ³ Medirex Group Academy n.p.o., Nitra, Slovakia
- 7 * Correspondence:
- 8 Nikola Janostiakova
- 9 nyariova1@uniba.sk

10 Keywords: COVID-19, pandemic, Slovakia, statistics, RT-qPCR, Ct value, age groups

11 Abstract

- The COVID-19 pandemic has been part of Slovakia since March 2020. Intensive laboratory testing ended in October 2022, when the number of tests dropped significantly, but the state of the pandemic continues to this day. For the management of COVID-19, it is important to find an indicator that can predict pandemic changes in the community. The average daily/weekly Ct value with a certain time delay can predict changes in the number of cases of SARS-CoV-2 infection, which can be a useful
- indicator for the healthcare system. The study analyzed the results of 1,420,572 RT-qPCR tests
 provided by one accredited laboratory during the ongoing pandemic in Slovakia from March 2020 to
 September 2022. The total positivity of the analyzed tests was 24.64%. The average Ct values found
- were the highest in the age group of 3-5 years, equal to the number 30.75; the lowest were in the age group > 65 years, equal to the number 27. The average weekly Ct values ranged from 22.33 (pandemic
- 21 group > 65 years, equal to the number 27. The average weekly Ct values ranged from 22.33 (pandemic 22 wave week) to 30.12 (summer week). We have summarized the results of SARS-CoV-2 diagnostic
- testing in Slovakia with the scope defined by the rate and positivity of tests carried out at Medirex a.s.
- 24 laboratories.

25 1 Introduction

26 The COVID-19 pandemic in Slovakia is part of the global pandemic of the disease COVID-19 caused

- by the SARS-CoV-2 virus. The first case was confirmed in Slovakia on March 6, 2020 [1]. The first
- 28 measures against the pandemic were also adopted on March 6, 2020 [2]. A state of emergency was first
- declared on March 12, 2020 [3]. The state of the pandemic continues worldwide to this day [4].
- 30 Strict rules and measures adopted in Slovakia at the beginning of the pandemic kept the number of
- 31 infected people relatively under control. The next wave of the pandemic during the winter of 2020/2021
- 32 brought a significant worsening of the situation [5]. Due to the appearance of a new alpha mutation
- 33 (B.1.1.7), this deterioration was even beyond the expectations of experts [6]. In February 2021,
- 34 Slovakia became the worst in the world in the number of deaths and hospitalized cases per capita [7].
- 35 The inability to predict the rate of change in the SARS-CoV-2 infection hindered the ability to
- 36 effectively respond to the crisis not only in Slovakia, but also in the world. The possible way how to

monitor disease spread and estimate the evolution of pandemic waves is to perform large scale
laboratory as well as home-based testing for the SARS-CoV-2 infection in the population and this was
adopted in our region. The most widely used laboratory test method for detecting the presence of the
SARS-CoV-2 virus in a sample is RT-qPCR (Quantitative Real-Time Reverse Transcription
Polymerase Chain Reaction). At November 22, 2022, Slovakia recorded a total of 1,855,129 positive
cases of coronavirus from 7,348,616 RT-qPCR tests performed (1,345,853 tests per 1 million
inhabitants) [8].

44 RT-qPCR detects and quantifies the monitored section of DNA in real time reaction. Amplification monitoring is based on the principle of fluorescence using probes (fluorescent substances) that bind 45 46 specifically or non-specifically to the amplified DNA. An amplification curve is created for each 47 examined sample based on the measured fluorescence signals [9]. For each amplification curve is then 48 determined a threshold value, referred as the Ct (threshold cycle), that is the intersection between an 49 amplification curve and a threshold line and determines the positivity of the test. The Ct value 50 represents the number of PCR cycles required for the fluorescence signal generated by the 51 incorporation of fluorescent dyes into the PCR product to exceed the background fluorescence level 52 [10]. It is a relative measure of the concentration of target in the PCR reaction. Low Ct values indicate 53 a high viral load and a potentially high level of infectivity. High Ct values indicate a very early or late 54 stage of infection, and therefore a potentially low level of infectivity [11].

For the surveillance of COVID-19, it is important to find a good indicator that can predict the trends of the pandemic in the community. The results of several studies indicate that the average daily/weekly Ct value with a certain time delay can predict the increase in the number of positive confirmed cases of COVID-19, which can be a useful indicator for the healthcare system [12, 13]. It is extremely important in diseases, which have a high potential to significantly increase the demand for hospitalization and cause an overcrowding of hospital capacities, threatening a standardly functioning healthcare system

62 For a more effective and sustainable management of the pandemic, it is necessary to predict the improvement/deterioration of the epidemiological situation and prevent its deterioration by following 63 64 a set of epidemiological criteria at the regional, national, and international level, so that measures are 65 tightened and loosened based on objective criteria [14]. The aim of the work was to summarize the 66 results of SARS-CoV-2 diagnostic testing in Slovakia at the regional level with the scope defined by 67 the rate of tests carried out in Medirex a.s. laboratories and with reference to the course of the pandemic evaluated at the national level. The number of this study data is robust, representing more than 1.4 68 million evaluated RT-qPCR tests. We made sure that the selection of the date period included the entire 69 70 timeline of the massive national testing of positivity/negativity of Covid-19 within the Slovak 71 Republic. We were particularly interested in individual parameters in terms of differences in viral load 72 over time and between characterized age subgroups (estimated using Ct values). Our findings regarding 73 the trends of the pandemic in the Slovak population can be used for a more effective setting of either 74 diagnostics or the logistics of measures in possible future epidemics/pandemics.

75 2 Article type

- 76 Original Research
- 77 3 Manuscript Formatting
- 78 **3.1 Materials and methods**

79 The study analyzed data provided by the accredited laboratory Medirex. The data represent the results 80 of RT-qPCR tests of patients and general population. Samples were evaluated from March 2020 to September 2022 and tests were performed in the Central Laboratories in Bratislava, Kosice and Nitra. 81 82 During this period, the laboratories analyzed 1,420,572 tests. The samples were collected from 74 83 (93.7%) districts of Slovakia. The representation of the districts in the study is connected with the 84 location of the sample collection points created during the SARS-CoV-2 pandemic testing and the 85 location of the diagnostic laboratories Medirex, a.s. In the case that the sample collection points of 86 certain districts of Slovakia were contracted another diagnostic laboratory, we did not have samples 87 from this district.

88 Laboratory Medirex, a.s. carried out tests for the general population and for patients based on a request 89 from a doctor as one of the state-contracted diagnostic laboratories in Slovakia. On the website 90 www.korona.gov.sk, citizens had the opportunity to request a SARS-CoV-2 detection test. The 91 Ministry of Health of the Slovak Republic recommended to use the possibility of testing with PCR 92 tests in case of suspicion of the disease COVID-19. If symptoms of infection were entered (e.g. 93 temperature above 38 degrees, dry cough, joint and muscle pain, shivering, coughing or loss of smell 94 or taste) or contact with a positively tested person, this testing was fully covered by public health 95 insurance. Based on the assessment of clinical symptoms, citizens were automatically assigned the 96 nearest possible testing date in the closest possible vicinity of the address they entered in the 97 application. A positive antigen test of citizen was another possibility to be tested similarly with the 98 PCR test - citizens could also verify positivity of antigen test by subsequently performing a PCR test, 99 which in this case was also covered by public health insurance. In addition to free testing in case of 100 symptoms of the SARS-CoV-2 infection, citizens had the opportunity to be tested free of charge with 101 PCR tests during pre-operative examinations or before planned hospitalization [15]. Finally, 102 individuals could undergo the PCR examination also as self-payers, in this case no selection of 103 individuals (assessment of the presence of symptoms, etc.) was necessary to perform the test. The 104 presence of SARS-CoV-2 was determined from nasopharyngeal swabs and saliva samples, since the 105 collection sites in Slovakia provided these two options for collecting genetic material. Automated 106 extraction of nucleic acid (DNA/RNA) on magnetic particles was performed using the Sera-Xtracta 107 Virus/Pathogen Kit (Cytiva) and the Zybio Nucleic Acid Extraction Kit (Zybio) using the 108 KingFisherTM Flex Purification System (Thermo Scientific) and Zybio EXM 3000 Nucleic Acid 109 Isolation System (Zybio) / Zybio EXM 6000 Nucleic Acid Isolation System (Zybio), respectively. 110 Testing was performed by RT-qPCR using the COVID-19 Real Time Multiplex RT-PCR Kit (Lab-111 systems Diagnostics), SARS-CoV-2 Nucleic Acid Detection Kit (Zybio) and Novel Coronavirus 112 (2019-nCoV) Real Time Multiplex RT-PCR Kit (Liferiver) on qPCR platforms ABI 7500 (Fast) Re-113 al-Time PCR System, OuantStudio 5 and OuantStudio 6 Real-Time PCR System (Applied Bio-114 systems). Data obtained for each test included daily sample number, collection date, patient ID, age, 115 sex, location of sample collection, test result and, in the case of a positive result, the Ct value of the 116 viral gene E – diagnostic value up to 40 (for the SARS-CoV-2 Nucleic kit Acid Detection Kit (Zybio)) 117 or 41 (for COVID-19 Real Time Multiplex RT-PCR Kit (Labsystems Diagnostics) and Novel 118 Coronavirus (2019-nCoV) Real Time Multiplex RT-PCR Kit (Liferiver)) - that mean 39 or 40 of 119 amplification cycles is needed to reach the threshold at which a molecular diagnostic test can be 120 detected with positive signal. Ct values have been reported and archived for a positive result since 121 2020-12-03 - therefore, results for Ct values include the date range December 2020 - September 2022.

Data were categorized into nine groups by age/level of school attended: newborns and toddlers (0-2 years); children of preschool age (3-5 years); children from primary school I (6-8 years old); children of primary school II (9-13 years); children of primary school III (14-15 years); youth I/secondary schools (16-19 years); youth II/university (20-26 years); adults (27-65 years) and sen-iors (66 years

126 and older). For the purposes of demographic analysis, the data were also categorized into individual

- districts/regions of Slovakia. Population data were obtained from census done by Statistical Office of the Slovak Population in 2021 [16]
- 128 the Slovak Republic in 2021 [16].

129 Various statistical tests were used to compare categories of data, check for correlations and data 130 characteristics. Fisher's exact test was used to compare values of positivity and Welch's t-test was used 131 to compare Ct values between different groups. Hartigans' dip test was used to check for unimodality 132 of data and Spearman's rank correlation coefficient was used to address possible correlations. Together

- 133 133 statistical tests were performed and Bonferroni correction was used to adjust the threshold of
- 134 significance for p-value. Thus 3.76E-4 was used as the threshold instead of 0.05.

135 **3.2 Results**

136 From March 2020 to September 2022, the laboratory performed a total of 1,420,572 tests for diagnostic

purposes, which for the given period represents more than 19% of the total number of RT-qPCR tests
 in Slovakia. To estimate how the representation of RT-qPCR tests in our study changed over time, we

determined the percentage representation of Medirex tests in relation to the total number of RT-qPCR

- tests in Slovakia on the last day of each month the representation of tests evaluated in Medirex, a.s.
- ranged from 8.72% (2022-08-31) to 57.34% (2021-01-31). The population source of the studied
- 142 population divided into the districts of Slovakia is shown in Figure 1. The color scale shows the number 143 of tests performed and positivity in individual districts. The total positivity of the analyzed tests was

of tests performed and positivity in individual districts. The total positivity of the analyzed tests was 24.64% (350,067 tests), while the highest rate of positivity (over 30%) was achieved by the age

145 categories: 6-8 years, 9-13 years, 14-15 years, 16-19 years. The age distribution of the tested patients

146 of the study, together with the frequency of positive/negative PCR tests and the corresponding rate of

147 positivity for individual age categories, is shown in Table 1.

148 The most PCR tests were performed in the Bratislava district, their total number was 612,427, which

149 is more than 6 times more compared to the Kosice district (2nd most numerous in tests performed -

150 100,838 RT-qPCR tests) (Fig. 1A). The rate of the number of tests per population reached 130% in the

Bratislava district (Fig. 1C). The highest total positivity (more than 40%) was achieved by the (45.02%) K = (47.01%) K =

152 following districts: Sabinov (45.9%), Trencin (49.25%), Komarno (47.01%), Kosice-okolie (45.16%) 153 (Fig. 1B). A more objective view of the rate of positivity in individual districts is represented by the

- 153 (Fig. 1B). A more objective view of the rate of positivity in individual districts is represented by the 154 recalculation of the number of positive RT-qPCR tests per district population. In this case, only the
- 155 district of Stropkov (42.615%) achieved positivity above 40%. (Figure 1D).

156 The map in Figure 2A visualizes the geographical division of Slovakia into 8 regions - Bratislava, 157 Trnava, Nitra, Trencin, Zilina, Banska Bystrica, Kosice and Presov. The graph of Figure 2B shows the differences in Ct values of positive PCR tests between individual regions. Differences in positivity 158 159 between all pairs of regions were found to be significant based on the Fisher exact test (p-value < 160 3.76E-4). A significant difference in Ct values was demonstrated on the basis of the independent 161 samples t-test between all pairs of regions, except for the pairs: BA-TT (p-value 0.99), BA-ZA (p-162 value 0.14), BA-KE (p-value 0.44), TT-ZA (p-value 0.14), TT-KE (p-value 0.57), NR-ZA (p-value 163 0.7), NR-BB (p-value 0.04), TN-ZA (p-value 0.8), ZA-BB (p-value 0.56), ZA-KE (p-value 0.15), ZA-PO (p-value 0.46), BB-PO (p-value 0.14). The average Ct values of individual regions were equal to 164

165 values from 26.57 to 27.72.

The number of tests performed per day with the corresponding number of positive tests is shown in Figure 3. The curve of test frequency and positivity in daily intervals is shown in Figure 3A. For comparison with our data, a similar distribution of frequency and positivity of all performed diagnostic tests within the national testing in Slovakia is shown in Figure 3B. Figure 4 shows the proportion of

- positivity of tests carried out within the study (4A) and, for comparison, the proportion of positivity of
- all tests carried out in Slovakia within the framework of national testing (4B). In Figure 4B, the data
- 172 from March 2020 to September 2022 are plotted with vertical yellow lines. The curves of the graphs
- show that the positivity rate followed the pandemic waves in Slovakia, which is also represented by the number of tests not formed even time (Figure 2, 4).
- the number of tests performed over time (Figure 3, 4).
- 175 Figure 5 shows the age distribution of tested individuals and positive individuals (5A), respectively the
- age distribution of tested and positive individuals depending on gender male/female (5B). Based on
- the Fisher exact test, the difference between the positivity of men (23.72%) and women (25.54%) was
- significant (p-value 1.36E-139). The most tested individuals were aged 43 (30,895 individuals). Based
- 179 on the performed Hartigans' dip test, the distribution of Ct values of positively tested individuals is
- probably not unimodal, while the average median of Ct values is equal to 27.9 (5C). The detected Ct
- values ranged from 9.5 to 41. Based on the independent samples t-test, significant differences in the
- average Ct values between men and women were demonstrated (p-value 5,88E-27) (5C). The highest
 average Ct values were achieved in the age group of 3-5 years, equal to the number 30.75, the lowest
- average Ct values were achieved in the age group of 3-5 years, equal to the number 30.75, the low average Ct values were achieved in the age group > 65 years and represented the number 27 (5D).
- 185 The average weekly Ct of our data reached values from 22.33 (week starting 01/28/2021 pandemic
- wave) to 30.12 (week starting 06/30/2022 pandemic on the wane) (6A). However, the correlation
- between the change in the number of positives with a one-week delay and the average Ct values based
- 188 on Spearman's rank correlation coefficient was not confirmed (p-value 0.52).
- 189 Figure 7 shows the distribution of Ct/total positivity values depending on the age of the individuals.
- 190 The violin chart demonstrates a gradual decrease in the median Ct values along with the increasing age
- of the categorized study groups. The highest value of the median Ct was found in the age group of 3-5 vrs. equal to the number 30.75. The lowest median Ct value was found in the 20-26 vrs and 27-65 vrs
- 192 yrs, equal to the number 30.75. The lowest median Ct value was found in the 20-26 yrs and 27-65 yrs 193 groups, equal to the number 26.7 (7A). Overall positivity above 30% was noted in patients aged 7-19
- yrs (7B). A significant difference in positivity between age categories was recorded on the basis of the
- Fisher exact test between all pairs, with the exception of pairs: 3-5 yrs (positivity 25.09%) and 20-26
- yrs (positivity 24.27%) (p-value 0.5); 6-8 yrs (positivity 33.61%) and 16-19 yrs (positivity 33.41%) (p-
- value 19.88). Significant differences in the average value of Ct within the age categories were
- demonstrated on the basis of the ndependent samples t-test in almost all pairs with the exception of: 0-
- 199 2 yrs and 6-8 yrs (p-value 7.04), 14-15 yrs and 16-19 yrs (p-value 0.2), 20-26 yrs and 27-65 yrs (p-
- 200 value 33.61), 20-26 y and > 65 yrs (p-value 9.86), 27-65 yrs and > 65 yrs (p-value 6.25).

201 **3.3 Discussion**

202 The COVID-19 pandemic has affected many areas of medicine and healthcare around the world. Its 203 further development is very difficult to predict. The situation is complicated by the fact that the virus 204 is able to constantly evolve and generate new mutations, which in a specific constellation can lead to 205 the emergence of new variants that can have different manifestations (infectivity, mortality). The 206 inability to predict increases or decreases in cases of SARS-CoV-2 infection has significantly affected 207 the ability of public health officials to respond to this crisis and take the necessary measures. Early 208 detection of the SARS-CoV-2 virus using diagnostic methods is therefore still crucial. The optimal 209 method continues to be the RT-qPCR method, which provides a high diagnostic potential thanks to the 210 currently well-developed laboratory infrastructure.

- In our study, we analyzed whether and how average weekly Ct values from RT-qPCR tests correlate
- with the occurrence of SARS-CoV-2 infection in a subpopulation of Slovak residents tested in one
- 213 accredited laboratory, the tested individuals were classified into age groups. The actual local

214 prevalence and the number of tests performed affect the value of the positivity rate. In general, as more 215 tests are deployed, the positivity rate will approach the true prevalence [19]. The analyzed tests of this 216 study represent > 19% of all diagnostic PCR tests in Slovakia (for the given date interval) from > 93% 217 of the districts of the Slovak Republic, so they should be representative of the population, which is also 218 shown by comparing the frequency and positivity curves of the tests in our study with the curves of the 219 data of the national Slovakia's Covid-19 PCR testing. Although the data showed that children in 220 primary and secondary schools (6-19 years old) had the highest positivity rate (Table 1, Figure 7B), 221 this phenomenon is probably related to the lower frequency of tests in the given age subgroup. In 222 addition, children had schools closed during much of the pandemic [20] and were not required to 223 undergo regular PCR testing (e.g. mandatory for some groups of employees in the workplace). 224 Therefore, children with symptoms of the disease apparently requested PCR diagnosis of SARS-CoV-225 2 as a priority, which could also have contributed to a higher rate of overall positivity in their age 226 subgroup.

227 The number of performed RT-qPCR tests in Slovakia was largely influenced by changes in the 228 availability of a free RT-qPCR test. From May 2022, a referral from a doctor (general practitioner or 229 specialist) is required to perform a free RT-qPCR test. The exception is patients over 60 years of age, 230 who can continue to request a free RT-qPCR examination through the state portal [21] in case of 231 symptoms of the disease. In the aforementioned study, a lower frequency of performed tests is detected 232 in the time interval April/May 2022. From mid-May 2022 until the end date of the analyzed data of the 233 study, which is September 28, 2022, a significantly reduced frequency of tests was subsequently 234 detected (Figure 3A). A possible limitation in the geographical (districts of Slovakia) classification of 235 performed and positively evaluated PCR tests could be the migration of residents (e.g. due to 236 employment) within districts without updating the permanent residence of citizens. In the result of our 237 study, this was confirmed by recalculating the number of tests performed in the Bratislava district to 238 the official number of inhabitants of this district - probably for this reason, the ratio of the number of 239 tests to the number of inhabitants of the Bratislava district reached up to 130%.

The results of several studies show that the distributions of Ct values in SARS-CoV-2 screening cases are typically bimodal [22, 23]. There is an assumption that a lower maximum Ct value corresponds to patients with high infectivity and a higher maximum Ct value corresponds to patients with low infectivity [23]. A bimodal distribution is also typical for other viral infections, with the lowest Ct values indicating the proportion of individuals with a high viral load in the acute phase of infection, and higher Ct values being typical for the early phase of infection or convalescence [11, 24, 25]. This assumption could explain why the distribution of average Ct values of our data is not unimodal.

247 There are also currently several studies determining the ability of Ct values to predict future cases of 248 COVID-19 in terms of outcomes [26, 27, 28]. Although in several published studies, summary analyzes 249 of the distribution of Ct values revealed that the average weekly Ct values fluctuated during the 250 pandemic and that a gradual decrease in the average weekly Ct values indicated a future increase in the 251 occurrence of positive samples [29], this trend was not confirmed by the results of the analysis on our 252 data. Most relevant potential reasons for this difference may be the chaotic organization of the 253 screening and diagnostics in Slovakia performed by the laboratories and relatively unspecific and 254 broadly described criteria regarding the public testing. As in our dataset no specific selection of samples 255 was done, e.g. positive for specific symptoms or based on origin related to specific organizations 256 indicating the test (hospitals, ambulances, selected collection points) the data could be not able to be 257 used for such evaluation and potential prognostic use.

258 Next, we focused on the distribution of Ct values in different age groups to determine which groups 259 may contribute the most to the spread of infection. Biomedical research today relies on p-values as a 260 deterministic measure for data-driven decision making, where a single p-value is calculated from 261 samples of data to determine statistically significant differences between groups of observations. 262 Because the estimated p-value tends to decrease with increasing sample size, applying this 263 methodology to data sets with large sample sizes leads to a higher probability of rejecting the null 264 hypothesis [30], which was also reflected in our data (more than 1.4 million RT-qPCR tests). This fact probably contributed to the demonstration of significant differences in the average Ct values between 265 266 almost all categorized age groups and also between the regions of Slovakia. This assumption is also 267 confirmed by the fact that the differences between the average Ct values of the Zilina region, which has the smallest number of samples (95 RT-qPCR tests), and the remaining regions were not significant 268 269 in any case. However, this does not mean that the observed significance is not real. On the contrary, 270 low p-values are present with large sample sizes because the robustness of data means that even a small 271 difference is more likely to reflect a real underlying difference between two datasets. We observe many 272 significant differences between various groups of patients and it can be explained by high complexity 273 of the pandemic. Although there were general trends followed by most patient groups, too many 274 variables participated in the outcome. Examples include infection outbreaks being present in different 275 locations at different times or high variability of measures for suppressing the pandemic.

276 However, the graph in Figure 7A demonstrates that the decrease in mean Ct values was consistent with 277 increasing age of individuals in age-related subgroups. This observation is consistent with the statement 278 that children with SARS-CoV-2 infection are often asymptomatic or mildly symptomatic and are rarely 279 the index case in household transmission chains [31]. There are several factors that can potentially 280 affect the detected Ct values, including the type of sample (e.g. nasopharyngeal, anterior nasal mucosa, 281 saliva, sputum) or the efficiency of sampling, (non-intensive sampling can lead to inaccuracies of the results) [32]. The detection of lower Ct values in children may be related to the quality of sampling, as 282 283 it is necessary to introduce the sampling rod into the nasopharynx [33]. Saliva sampling was put into 284 practice precisely because of the complications of sampling from the nasopharynx in certain groups of 285 individuals - significant pain during nasopharyngeal swabs was described by 58% of young people 286 compared to none during saliva sampling, while 90% of children prefer saliva sampling [34]. The 287 results of the articles demonstrate that detection from saliva samples performs as well or better than 288 nasopharyngeal swabs in hospital, emergency care and mass screening settings for SARS-CoV-2 289 testing by RT-qPCR [35-38]. However, the average Ct value in saliva can be higher compared to the 290 average Ct value from nasopharyngeal swabs [39]. Therefore, a combined nasal and throat swab is 291 usually recommended as a more suitable sample for RT-qPCR diagnosis [32]. As we wanted to include 292 in this study all samples from March 2020 - September 2022 provided by the Medirex laboratory with 293 a positive/negative result detected, the data includes both nasopharyngeal swabs and saliva samples. 294 However, the results representing the detection of SARS-CoV-2 from saliva samples represent less 295 than 5% of all samples and therefore we do not assume that this fact could affect the overall informative 296 value of the average Ct values for the data of this study.

297 3.4 **Conclusions**

298 The age of patients was the most relevant individual parameter when it comes to differences in the 299 viral load as clinically relevant and patient cohort characteristics. The lower age was associated with

300 higher Ct values, and so with lower viral load, and decreased with the age increase. This finding

301 could be used in the public services or lockdown planning during pandemic, e.g. to let the schools

302 open could be less risky when it comes to disease spread in comparison to other public services.

304 social measures should be based primarily on a situational assessment of the intensity of

305 transmission, the vaccination rate of the population and the ability of the health system to respond to 306 a pandemic.

307 3.5 Figures



308 Figure 1: Geographical classification of the examined and positively tested population according to 309 the districts of Slovakia. (A) On the map, each district has a colored representation (log2 scale) 310 corresponding to the number of tests performed. For each color of the scale, the number of tests 311 corresponding to each color is indicated. (B) Each district has a colored representation (linear scale) 312 on the map that corresponds to the total positivity of the district. For each color of the scale, the 313 positivity rate (%) corresponding to the individual colors is given. Non-representative districts with 314 insufficient sample representation (less than 50 samples) to calculate total positivity are shown in gray. 315 (C) Each district has a color representation on the map (log2 scale) that corresponds to the rate of tests performed per district population. For each color of the scale, the rate of frequency (%) corresponding 316 317 to individual colors is given. (D) Each district has a representation on the map (log2 scale) 318 corresponding to the rate of positive tests for the population of individual districts of Slovakia. For 319 each color of the scale, the positivity rate (%) corresponding to the individual colors is given

320

321



Figure 2: (A) Geographical visualization of individual regions of the Slovak Republic. Explanations:

- 324 BA Bratislava region, TT Trnava region, NR Nitra region, TN-Trencin region, ZA Zilina
- 325 region, BB Banska Bystrica region, KE Kosice region, PO Presov region [17]. (B) Distribution
- of Ct values of positive diagnostic tests of individual regions of Slovakia shown as boxplots,
- 327 supplemented by median Ct values (red lines).



Figure 3: (A) Distribution of study PCR diagnostic tests performed per day (blue curve), corresponding
number of positive study tests per day (red curve), compared with (B) distribution of all diagnostic
tests performed per day within the Slovakian PCR testing (blue curve), corresponding number of
positive tests within the Slovakian PCR testing (red curve) [5]. (A, B) graphs show the date range 202003-19 to 2022-09-29.



Figure 4: (A) Distribution of proportion of positive diagnostic tests of study performed per day, compared with (B) distribution of proportion of all positive tests per day within the Slovakian PCR testing [18]. Parallel yellow lines (B) define the period from 2020-03-19 to 2022-09-28.

- 354
- 355
- 356



Figure 5: (A) Age distribution of all tested individuals (blue curve), positively tested individuals (red curve). (B) Age distribution of all tested women (green curve), positive tested women (red curve), all tested men (blue curve), positive tested men (pink curve). (C) Ct distribution of all diagnostic tests (black curve), tests performed in females (red curve) tests performed in males (blue curve). (D) Ct distribution of all diagnostic tests. The data is broken down by the age of the individuals.

- 362
- 363
- 364
- 365
- 366
- 367
- 368
- 369
- 370



Figure 6: (A) Ct distributions of positive diagnostic tests shown as boxplots, supplemented by Ct median values (orange segments). (B) Time course of median Ct per day (black curve) and change of ratio posite tests per day with one week delay (red curve). (A, B) Gaps in the graphs reconstruct pandemic days/ weeks with an insufficient number of samples (less than 50 performed PCR tests) non-representative results not included in the evaluation.



Figure 7: (A) Distribution of Ct positive diagnostic tests in different age groups. Data are displayed as
violin charts and notched boxplots supplemented with Ct median values (orange segments). (B)
Distribution of positivity rate by age of individuals (green curve) and distribution of number of tests
by age of individuals (blue curve).

381 **3.6 Tables**

382 Table 1: Number of positive/negative tests and total positivity of tests for individual age categories.

383 Age distribution of the tested individuals along with the corresponding positivity rate, calculation of

the total positivity of the study tests.

Age group	Positive	Negative	Total	Positivity (%)
0-2	1,806	9,273	11,079	16.30%
3-5	4,757	14,201	18,958	25.09%
6-8	10,689	21,112	31,801	33.61%
9-13	26.193	42.544	68.737	38.11%
14-15	9,983	17.968	27.951	35.72%
16-19	18,839	37,543	56.382	33.41%
20-26	28 861	90.078	118 939	24 27%
27-65	216 104	703 904	920.008	23.49%
<u>~65</u>	32 835	133 882	166 717	19.70%
Total	350,067	1,070,505	1,420,572	24.64%

385

386 4 References

- 387[1]MinisterstvozdravotnictvaSR.Availableonline:388https://www.health.gov.sk/Clanok?koronavirus-pripad-prvy-opatrenia(accessedon23rd389November [22).
- 390[2]MinisterstvozdravotnictvaSR.Availableonline:391https://www.health.gov.sk/Clanok?koronavirus-krizovy-stab-opatrenia(accessedon23rd392November 2022).

393 [3] Ministerstvo zdravotnictva SR. Available online: 394 https://www.health.gov.sk/Clanok?koronavirus-opatrenia-sprisnene (accessed 23rd on 395 November 2022). 396 WHO. Available online: https://www.who.int/news/item/30-01-2023-statement-on-the-[4] 397 fourteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committeeregarding-the-coronavirus-disease-(covid-19)-pandemic (accessed on 3rd March 2023). 398 399 [5] NCZI. Available online: https://covid-19.nczisk.sk/sk (accessed on 7th March 2023). 400 UVZSR. online: [6] Available 401 https://www.uvzsr.sk/index.php?option=com_content&view=article&id=4590:britska-mutacia-402 bola-na-slovensku-u-v-novembri-v-trenine-mohla-pred-sviatkami-403 dominova&catid=250:koronavirus-2019-ncov&Itemid=153 (accessed on 23rd November 2022). 404 [7] Our world in data. Available online: https://ourworldindata.org/explorers/coronavirus-data-405 explorer?zoomToSelection=true&time=2021-02-406 11&facet=none&pickerSort=desc&pickerMetric=location&hideControls=true&Metric=Confir 407 med+deaths&Interval=7-408 day+rolling+average&Relative+to+Population=true&Color+by+test+positivity=false&country= 409 GBR~CZE~SVK~USA~LTU~MCO (accessed on 23rd November 2022). 410 Covid2019. Available online: https://www.covid2019.sk/koronavirus-v-europe/koronavirus-v-[8] 411 slovenskej-republike/ (accessed on 23rd November 2022). 412 Mackay, I.M. Real-time PCR in the microbiology laboratory. Clin Microbiol Infect. 2004, [9] 10(3):190-212. 413 414 [10] Rao, S.N.; Manissero D.; Steele V.R.; Pareja J. A Systematic Review of the Clinical Utility of 415 Cycle Threshold Values in the Context of COVID-19. Infect Dis Ther 2020, 9(3): 573-586. 416 [11] Tom, M.R.; Mina, M.J. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. 417 Clin Infect Dis. 2020, 71(16): 2252-4. 418 [12] Dehesh, P.; Baradaran, H.R.; Eshrati, B.; Motevalian, S.A.; Salehi, M.; Donyavi, T. The 419 Relationship Between Population-Level SARS-CoV-2 Cycle Threshold Values and Trend of 420 COVID-19 Infection: Longitudinal Study. JMIR Public Health Surveill. 2022, 8;8(11): e36424. 421 [13] Hay, J.A.; Kennedy-Shaffer, L.; Kanjilal, S.; Lennon, N.J.; Gabriel, S.B.; Lipsitch, M.; Mina, 422 M.J. Estimating epidemiologic dynamics from cross-sectional viral load distributions. Science 423 2021, 16;373(6552): eabh0635. 424 [14] MIRRI. Available online: https://korona.gov.sk/wp-425 content/uploads/2021/11/covid_automat_signalizacny_system_4v3.pdf (accessed on 5th April 426 2023). 427 [15] Ministerstvo zdravotnictva SR. Available online: https://www.health.gov.sk/Clanok?test-pcr-428 ochorenie (accessed on 5th April 2023). 429 Statisticky urad Slovenskej republiky. Available online: https://www.scitanie.sk/ (accessed on [16] 430 5th April 2023). 431 [17] Wikipedia. Available online: 432 https://sk.wikipedia.org/wiki/Okres %28Slovensko%29#/media/S%C3%BAbor:Okresy97 Slov 433 akia.svg (accessed on 5th April 2023). 434 [18] Bot.Media. Available online: https://mapa.covid.chat/ (accessed on 7th March 2023).

- [19] Montesinos-López, J.C.; Daza-Torres, M.L.; García, Y.E.; Barboza, L.A.; Sanchez, F.; Schmidt,
 A.J.; Pollock, B.H.; Nuño, M. The Role of SARS-CoV-2 Testing on Hospitalizations in
 California. Life 2021, 11, 1336.
- 438[20]MinisterstvozdravotnictvaSR.Availableonline:439https://www.health.gov.sk/Clanok?koronavirus-opatrenia-mimoriadne(accessed on 23rd440November 2022).
- [21] Dovera. Available online: https://www.dovera.sk/aktuality/4897-na-pcr-test-uz-treba-vymenny listok (accessed on 19th December 2022).
- [22] Humphreys, D.P.; Gavin, K.M.; Olds, K.M.; Bonaca, M.P.; Bauer, T.A. At-home sample
 collection is an effective strategy for diagnosis and management of symptomatic and
 asymptomatic SARS-CoV-2 carriers. BMC Infectious Diseases. 2022, 22(1), 1–10.
- 446 [23] Mokhtar, K.M. Improved RT-PCR SARS-Cov2 results interpretation by indirect determination
 447 of cut-off cycle threshold value. MedRxiv, 2020.
- [24] Piubelli, C.; Deiana, M.; Pomari, E.; Silva, R.; Bisoffi, Z.; Formenti, F.; Perandin, F.; Gobbi, F.;
 Buonfrate, D. Overall decrease in SARS-CoV-2 viral load and reduction in clinical burden: the
 experience of a hospital in northern Italy. Clin Microbiol Infec. 2021, 27(1).
- [25] Jones, T.C.; Biele, G.; Muhlemann, B.; Veith, T.; Schneider, J.; Beheim-Schwarzbach, J.;
 Bleicker, T.; Tesch, J.; Schmidt, M.L.; Sander, L.E.; Kurth, F.; Menzel, P.; Schwarzer, R.;
 Zuchowski, M.; Hofmann, J.; Krumbholz, A.; Stein, A.; Edelmann, A.; Corman, V.M.; Drosten,
 C. Estimating infectiousness throughout SARS-CoV-2 infection course. Science 2021,
 373(6551).
- [26] Walker A.S.; Pritchard E.; House T.; Robotham, J.V.; Birrell, P.J.; Bell, I.; Bell, J.I.; Newton,
 J.N.; Farrar, J.; Diamond, I.; Studley, R.; Hay, J.; Vihta, K. D.; Peto, T. E.; Stoesser, N.; Matthews,
 P. C.; Eyre, D. W.; Pouwels, K. B.; COVID-19 Infection Survey team. Ct threshold values, a
 proxy for viral load in community SARS-CoV-2 cases, demonstrate wide variation across
 populations and over time. Elife 2021,12;10: e64683.
- [27] Yin, N.; Dellicour, S.; Daubie, V.; Franco, N.; Wautier, M.; Faes, C.; Van Cauteren, D.; Nymark,
 L.; Hens, N.; Gilbert, M.; Hallin, M.; Vandenberg, O. Leveraging of SARS-CoV-2 PCR cycle
 thresholds values to forecast COVID-19 trends. Front. Med. (Lausanne) 2021, 1;8: 743988.
- [28] Tso, C.F.; Garikipati, A.; Green-Saxena, A.; Mao, Q.; Das, R. Correlation of population SARS CoV-2 cycle threshold values to local disease dynamics: exploratory observational study. JMIR
 Public Health Surveill. 2021, 7(6): e28265.
- [29] Musalkova, D.; Piherova, L.; Kwasny O.; Dindova Z.; Stancik L.; Hartmannova H.; Slama O.;
 Peckova P.; Pargac J.; Minarik G.; Zima T.; Bleyer A. J.; Radina M.; Pohludka M.; Kmoch S.
 Trends in SARS-CoV-2 Cycle Threshold Values in the Czech Republic from April 2020 to April
 2022. Sci. Rep. 2023, 13(1):6156.
- [30] Gómez-de-Mariscal, E., Guerrero, V., Sneider, A.; Jayatilaka, H.; Phillip, J.M.; Wirtz, D.;
 Muñoz-Barrutia, A. Use of the p-values as a size-dependent function to address practical
 differences when analyzing large datasets. Sci Rep, 2021, 11, 20942.
- [31] Zhu, Y.S.; Bloxham, C.J.; Hulme, K.D.; Sinclair, J.E.; Tong, Z.W.M; Steele, L.E.; Noye, E.C.;
 Lu, J.H.; Xia, Y.; Chew, K.Y.; Pickering, J.; Gilks, C.; Bowen, A.C.; Short, K.R.A Meta-analysis
 on the Role of Children in Severe Acute Respiratory Syndrome Coronavirus 2 in Household
 Transmission Clusters. Clin. Infect. Dis. 2021, 72(12): E1146-E53.
- 478 [32] Yoo, H.M.; Kim, I.H.; Kim, S. Nucleic Acid Testing of SARS-CoV-2. Int. J. Mol. Sci. 2021, 22,
 479 6150.

- 480 [33] AACC. Available online: https://www.aacc.org/science-and-research/covid-19 481 resources/statements-on-covid-19-testing/aacc-recommendation-for-reporting-sars-cov-2-cycle 482 threshold-ct-values (accessed on 24th March 2023).
- 483 [34] Gagnon, F., Bhatt, M., Zemek, R., Webster, R. J., Johnson-Obaseki, S., Harman, S.
 484 Nasopharyngeal swabs vs. saliva sampling for SARS-CoV-2 detection: A cross-sectional survey
 485 of acceptability for caregivers and children after experiencing both methods. PloS one, 2020,
 486 7(7), e0270929.
- 487 [35] Huang C., Wang Y., Li X., Zhao J., Hu Y., Zhang L., et al. Clinical features of patients infected
 488 with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223):497-506.
- 489 [36] Ponti G., Maccaferri M., Ruini C., Tomasi A., Ozben T. Biomarker associated with COVID-19
 490 disease progression. Crit Rev Clin Lab Sci, 2020:1–11.
- [37] Zaninotto M., Mion M., Cosma C., Rinaldi D., Plebani M. Presepsin in risk stratification of
 SARS-CoV-2 patients. Clin Chim Acta, 2020, 507:161–3.
- 493 [38] Hansen C.B., Bayarri-Olmos R., Kristensen M.K., Pilely K., Hellemann D., Garred P.
 494 Complement related pattern recognition molecules as markers of short-term mortality in intensive
 495 care patients. J Infect, 2020, 80(4):378–87.
- [39] Torres, M., Collins, K., Corbit, M., Ramirez, M., Winters, C. R., Katz, L., Ross, M., Relkin, N.,
 Zhou, W. Comparison of saliva and nasopharyngeal swab SARS-CoV-2 RT-qPCR testing in a community setting. J infect., 2021, 82(4):84-123.
- 499

500 **5 Ethics statement**

501 The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethical

- 502 committee of Bratislava Self-Governing District under the identifier 03228/2021/HF from January 12,
- 503 2021. All patients have filled the questionnaires with relevant information regarding their health status
- 504 in relation to COVID-19 and signed informed consent.

505 6 Conflict of Interest

Andrej Gnip and Gabriel Minarik are employees of Medirex Group Academy n.p.o., Nitra, Slovakia.
 Emilia Mikova and Elena Tibenska are employees of Medirex, a.s., Pezinok, Slovakia. Other authors
 declare that the research was conducted in the absence of any commercial or financial relationships

509 that could be construed as a potential conflict of interest.

510 **7** Author Contributions

511 Conceptualization, GM and VR; methodology, GM, AG and NJ; software, AG; validation, GM and 512 NJ; formal analysis, AG; investigation, DK, GB and RS; resources, EM and ET; data curation, EM and 513 ET; writing—original draft preparation, NJ; writing—review and editing, GM; visualization, NJ, GM 514 and AG; supervision, GM; project administration, GM; funding acquisition, GM and VR. All authors 515 have read and agreed to the published version of the manuscript. All authors contributed to the article

- 516 and approved the submitted version.
- 517 **8 Funding**

- 518 This work was supported by the OPII program as the project Research on COVID-19 progressive
- 519 diagnostic methods and biomarkers useful in early detection of individuals at increased risk of severe
- 520 disease, ITMS: 313011ATA2, co-financed by the ERDF.

521 9 Acknowledgments

522 The authors thank the laboratory Medirex, a.s. for providing data for the study.

523 10 Supplementary Material

524 The following supporting information - table with all samples and laboratory information included in 525 the analysis can be downloaded at:

526 11 Data Availability Statement

527 NA.